CTLA-4/CD152[Biotin], His & Avi, Human
| ¥3300 | |
| Z04436-100 | |
|
|
|
|
|
|
|
|
|
| ¥3300 | |
| Z04436-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Conjugate | Biotin | ||||||
| Purity | > 95% as determined by BisTris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 16.3 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 25-30 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized CTLA-4/CD152[Biotin], His & Avi, Human His Tag at 1 μg/ml (100 μl/well) on the streptavidin precoated plate(5 μg/ml). Dose response curve for Human B7-1, hFc Tag with the EC50 of 2.4 ng/ml determined by ELISA. »
Immobilized Anti-CTLA-4 Antibody, hFc Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for CTLA-4/CD152[Biotin], His & Avi, Human, His Tag with the EC50 of 45.7 ng/ml determined by ELISA. »
The purity of CTLA-4/CD152[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC. »
CTLA-4/CD152[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), also known as CD152, is a protein receptor that, functioning as an immune checkpoint, downregulates immune responses.CTLA4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation – a phenomenon which is particularly notable in cancers. It acts as an 'off' switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. |
| Synonyms | CTLA4; CD152; ICOS; CELIAC3; GRD4; GSE; ALPS5; IDDM12 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.